Stockreport

Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus [Yahoo! Finance]

Galapagos NV - American Depositary Shares  (GLPG) 
Last galapagos nv - american depositary shares earnings: 10/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: glpg.com/company-overview
PDF In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical [Read more]